Translational research in regenerative medicine: A translational gap

Research output: Contribution to journalArticle

Abstract

A medical system is anticipated, where high-quality medical services are accessible without anxieties whenever we are ill. Innovative cell-based regenerative medical/medicinal products, and tissue-engineered medical products, have been used successfully to overcome certain life-threatening diseases, and there is still a need to design/produce more of these products. We translational researchers in regenerative medicine have been trying to translate our scientific findings from bench to bedside. Advanced therapies with cell-based regenerative medical/medicinal products constitute one of the most complex regulatory areas currently approached by clinical research and development in order to generate novel therapeutic applications for patients with incurable disease. We often lack the multidisciplinary skills needed to overcome intricate and complex regulatory tracks and might feel tired from pursuing clinical realization. Basic researchers and clinicians trying to translate stem cell biology into clinical practice might feel defeated by the endless regulatory requirements that apply. In order to help bridge this gap, in this chapter, we review practical issues that must be confronted in order to move from confidence in mechanism studies in animals into proof of concept studies in human. First, we briefly outline the basic definitions for cell products in the USA, EU and Japan, followed by a focused discussion of the pertinent actions of authorities in Japan.

Original languageEnglish
Pages (from-to)163-172
Number of pages10
JournalPharmaceuticals Policy and Law
Volume15
Issue number3-4
DOIs
Publication statusPublished - 01-12-2013
Externally publishedYes

Fingerprint

Regenerative Medicine
Translational Medical Research
Japan
Research Personnel
Cell- and Tissue-Based Therapy
Cell Biology
Stem Cells
Anxiety
Research
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

@article{b7eccdfa10d84f1293e08ed9b7e34899,
title = "Translational research in regenerative medicine: A translational gap",
abstract = "A medical system is anticipated, where high-quality medical services are accessible without anxieties whenever we are ill. Innovative cell-based regenerative medical/medicinal products, and tissue-engineered medical products, have been used successfully to overcome certain life-threatening diseases, and there is still a need to design/produce more of these products. We translational researchers in regenerative medicine have been trying to translate our scientific findings from bench to bedside. Advanced therapies with cell-based regenerative medical/medicinal products constitute one of the most complex regulatory areas currently approached by clinical research and development in order to generate novel therapeutic applications for patients with incurable disease. We often lack the multidisciplinary skills needed to overcome intricate and complex regulatory tracks and might feel tired from pursuing clinical realization. Basic researchers and clinicians trying to translate stem cell biology into clinical practice might feel defeated by the endless regulatory requirements that apply. In order to help bridge this gap, in this chapter, we review practical issues that must be confronted in order to move from confidence in mechanism studies in animals into proof of concept studies in human. First, we briefly outline the basic definitions for cell products in the USA, EU and Japan, followed by a focused discussion of the pertinent actions of authorities in Japan.",
author = "Akifumi Matsuyama",
year = "2013",
month = "12",
day = "1",
doi = "10.3233/PPL-130368",
language = "English",
volume = "15",
pages = "163--172",
journal = "Pharmaceuticals Policy and Law",
issn = "1389-2827",
publisher = "IOS Press",
number = "3-4",

}

Translational research in regenerative medicine : A translational gap. / Matsuyama, Akifumi.

In: Pharmaceuticals Policy and Law, Vol. 15, No. 3-4, 01.12.2013, p. 163-172.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Translational research in regenerative medicine

T2 - A translational gap

AU - Matsuyama, Akifumi

PY - 2013/12/1

Y1 - 2013/12/1

N2 - A medical system is anticipated, where high-quality medical services are accessible without anxieties whenever we are ill. Innovative cell-based regenerative medical/medicinal products, and tissue-engineered medical products, have been used successfully to overcome certain life-threatening diseases, and there is still a need to design/produce more of these products. We translational researchers in regenerative medicine have been trying to translate our scientific findings from bench to bedside. Advanced therapies with cell-based regenerative medical/medicinal products constitute one of the most complex regulatory areas currently approached by clinical research and development in order to generate novel therapeutic applications for patients with incurable disease. We often lack the multidisciplinary skills needed to overcome intricate and complex regulatory tracks and might feel tired from pursuing clinical realization. Basic researchers and clinicians trying to translate stem cell biology into clinical practice might feel defeated by the endless regulatory requirements that apply. In order to help bridge this gap, in this chapter, we review practical issues that must be confronted in order to move from confidence in mechanism studies in animals into proof of concept studies in human. First, we briefly outline the basic definitions for cell products in the USA, EU and Japan, followed by a focused discussion of the pertinent actions of authorities in Japan.

AB - A medical system is anticipated, where high-quality medical services are accessible without anxieties whenever we are ill. Innovative cell-based regenerative medical/medicinal products, and tissue-engineered medical products, have been used successfully to overcome certain life-threatening diseases, and there is still a need to design/produce more of these products. We translational researchers in regenerative medicine have been trying to translate our scientific findings from bench to bedside. Advanced therapies with cell-based regenerative medical/medicinal products constitute one of the most complex regulatory areas currently approached by clinical research and development in order to generate novel therapeutic applications for patients with incurable disease. We often lack the multidisciplinary skills needed to overcome intricate and complex regulatory tracks and might feel tired from pursuing clinical realization. Basic researchers and clinicians trying to translate stem cell biology into clinical practice might feel defeated by the endless regulatory requirements that apply. In order to help bridge this gap, in this chapter, we review practical issues that must be confronted in order to move from confidence in mechanism studies in animals into proof of concept studies in human. First, we briefly outline the basic definitions for cell products in the USA, EU and Japan, followed by a focused discussion of the pertinent actions of authorities in Japan.

UR - http://www.scopus.com/inward/record.url?scp=84893757654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893757654&partnerID=8YFLogxK

U2 - 10.3233/PPL-130368

DO - 10.3233/PPL-130368

M3 - Article

AN - SCOPUS:84893757654

VL - 15

SP - 163

EP - 172

JO - Pharmaceuticals Policy and Law

JF - Pharmaceuticals Policy and Law

SN - 1389-2827

IS - 3-4

ER -